The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis

The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis

Patients with MPNs commonly experience complications caused by dysfunctional haemostasis and thrombosis. Patient treatment is limited and aimed at preventing these adverse events, typically by low-dose aspirin therapy. However, a subset of patients experience increased risk of bleeding diatheses and...

Full description

Bibliographic Details
Main Author: Cosgrove, Megan
Other Authors: Hitchcock, Ian
Published: University of York 2016
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.701476
id ndltd-bl.uk-oai-ethos.bl.uk-701476
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-7014762017-10-04T03:41:12ZThe role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosisCosgrove, MeganHitchcock, Ian2016Patients with MPNs commonly experience complications caused by dysfunctional haemostasis and thrombosis. Patient treatment is limited and aimed at preventing these adverse events, typically by low-dose aspirin therapy. However, a subset of patients experience increased risk of bleeding diatheses and these patients are at an even greater risk for experiencing complications if they are treated with low-dose aspirin. Currently, there are no methods for stratifying MPN patients to distinguish those who are at risk for thrombosis or bleeding. In order to improve MPN patient treatment, a better understanding of the mechanisms behind haemostasis and thrombosis complications is required. Here, we investigate the mechanisms of JAK2V617F activation in endothelial cells and the effects of JAK2V617F on endothelial function.University of Yorkhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.701476http://etheses.whiterose.ac.uk/15863/Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
description Patients with MPNs commonly experience complications caused by dysfunctional haemostasis and thrombosis. Patient treatment is limited and aimed at preventing these adverse events, typically by low-dose aspirin therapy. However, a subset of patients experience increased risk of bleeding diatheses and these patients are at an even greater risk for experiencing complications if they are treated with low-dose aspirin. Currently, there are no methods for stratifying MPN patients to distinguish those who are at risk for thrombosis or bleeding. In order to improve MPN patient treatment, a better understanding of the mechanisms behind haemostasis and thrombosis complications is required. Here, we investigate the mechanisms of JAK2V617F activation in endothelial cells and the effects of JAK2V617F on endothelial function.
author2 Hitchcock, Ian
author_facet Hitchcock, Ian
Cosgrove, Megan
author Cosgrove, Megan
spellingShingle Cosgrove, Megan
The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis
author_sort Cosgrove, Megan
title The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis
title_short The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis
title_full The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis
title_fullStr The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis
title_full_unstemmed The role of JAK2V617F-positive endothelial cells in aberrant haemostasis and thrombosis
title_sort role of jak2v617f-positive endothelial cells in aberrant haemostasis and thrombosis
publisher University of York
publishDate 2016
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.701476
work_keys_str_mv AT cosgrovemegan theroleofjak2v617fpositiveendothelialcellsinaberranthaemostasisandthrombosis
AT cosgrovemegan roleofjak2v617fpositiveendothelialcellsinaberranthaemostasisandthrombosis
_version_ 1718545838855159808

Similar Items